ABT

Outcome

—

Return

—

Status

—

Subscribe to read

Outcome

—

Return

—

Status

—

Subscribe to read

Outcome

✓

Return

+1.13%

Status

scored

Maintain the 30-50% residual position at Hold (modestly below benchmark weight) while preserving the Underweight directional lean and awaiting the Q3 binary catalyst in mid-to-late October. Do not add ahead of the print or trim into the lower Bollinger band at $96.63, as both actions are prohibited by binding prior reflections. Pre-committed post-print rules include: exit residual next session on Q3 miss or guide below $6.00; add only on reclaim of 200 SMA above $102.65 with volume >20M and RSI >50 on beat; hold with trailing stop tightened to $96 on in-line print. The 2.55% dividend yield provides 7bp/quarter carry while waiting, but does not justify full weight given 14-16% downside risk to May lows ($83-85) versus 2.55% annual pickup.

Outcome

✓

Return

-0.24%

Status

scored

Maintain Underweight at 30-50% residual from prior trim, overriding the trader's Sell at $98.73 which violates the binding 10/06 reflection prohibiting fresh trimming of an Aristocrat with intact dividend coverage ahead of a binary catalyst. The position has a hard stop at $96.98 (lower Bollinger band) and pre-committed Q3 2026 earnings rules: beat (EPS +5%, guide maintained) → hold residual and add only on close above $103 on volume >20M; miss (EPS -5% or guide below $6.00) → exit residual next session; in-line → hold with trailing stop tightened to $96. Re-engagement requires two-of-four confirmations post-Q3 including MACD higher low, RSI bullish divergence, or forward EPS reaffirmation at $6.00+.

Outcome

✗

Return

+0.58%

Status

scored

Maintain Underweight rating with existing 30-50% residual position and $96.98 stop loss; $103 is the hard invalidation level for thesis upgrade, not a trim entry, as the 10/05 binding reflection prohibits further trimming into the relief-rally zone with intact dividend coverage. Pre-committed Q3 rules govern the next catalyst: beat scenario (EPS +5%, guide maintained) holds residual and adds only on close above $103 with volume >20M; miss scenario (EPS -5% or guide below $6.00) exits residual next session; in-line scenario holds with trailing stop tightened to $96. Re-engagement from Underweight to upgrade requires two-of-four confirmations including close above $103 on volume >20M, MACD histogram higher low, RSI bullish divergence at oversold, or forward EPS reaffirmation at $6.00+ with Nutrition stabilization.

Outcome

✓

Return

-1.94%

Status

scored

Maintain Underweight rating on Abbott Laboratories at the 30-50% residual position from the 10/01 trim, with a $97 price target reflecting tier-2 breakdown risk on Q3 disappointment. The 10/02 binding reflection explicitly prohibits further trimming into dividend-supported floors—DO NOT execute the trader's Sell at $105 into the 50 SMA resistance zone, as the position architecture and pre-committed Q3 rules (beat → hold; miss → exit; in-line → hold with $96 trailing stop) already capture the binary asymmetry without additional trim exposure.

Outcome

✗

Return

+2.67%

Status

scored

Maintain Underweight rating on Abbott Laboratories at 30-50% of target weight, with a $89.50 hard closing stop and $95 protective puts as defensive insurance into Q3 earnings (~2 weeks out). Pre-committed rules govern the binary catalyst: Beat (+5% EPS with raised guidance) → hold residual and add on close above 200 SMA ($103.14) on volume >20M shares; Miss (-5% EPS or guide-down below $6.00) → exit residual next session; In-line → hold with trailing stop tightened to $96. Re-engagement requires two-of-four confirmations post-Q3. The dividend carry (2.61% yield) pays for the wait through the binary.

Outcome

✗

Return

+0.84%

Status

scored

Underweight confirmed with 50-70% trim to execute immediately at $96-97—not deferred—while replacing the broken $100.70 stop (which sits above entry, functioning as a stop-gain) with a hard stop at $94 (May 2026 swing low zone). A 15-20% pre-earnings de-risking tranche in the week before Q3 2026 print drops residual from 50-55% to 35-40% target weight, with pre-defined Q3 rules: beat (EPS +5% with maintained/raised guidance) → hold; miss (EPS -5% or guide-down) → exit next day; freed capital parks in cash pending two-of-four re-engagement confirmations post-Q3.

Outcome

✓

Return

-2.17%

Status

scored

Underweight is the calibrated response when three bearish dimensions (technicals, fundamentals, macro) align against a still-intact Dividend Aristocrat floor ahead of a binary catalyst. Execute a ~50% trim immediately at current levels ($98-99), tighten the residual stop to $103 (not $107), and scale out an additional 15-20% in the week before the Q3 2026 earnings print. Re-engagement requires two-of-four confirmations post-Q3: close above 200 SMA on volume >20M shares, MACD higher low, RSI bullish divergence, or forward EPS reaffirmation at $6.00+.

Outcome

✓

Return

-2.10%

Status

scored

Maintain Underweight rating with 25-30% trim (position at 70-75% of target weight), adding an additional 15-20% pre-earnings de-risk in the week before Q3 to neutralize gap-down stop-fill risk, dropping to 50-55% through the binary catalyst; hard closing stop at $98.08 on residual position. Re-engagement requires two-of-four confirmations post-Q3 including close above 200 SMA ($103.53) on volume >20M shares, MACD higher low, RSI bullish divergence, or forward EPS reaffirmation at $6.00+ with Nutrition stabilization.

Outcome

–

Return

-0.03%

Status

scored

Active Underweight call requiring decisive 25-30% trim execution at current levels ($100-102), targeting 50-75% of benchmark weight with absolute exposure capped at 3-4% of portfolio equity, maintaining dividend carry on residual through the Q3 2026 binary earnings catalyst while hard stop exits residual below $99.95.

Outcome

–

Return

-0.31%

Status

scored

The rating is maintained at UNDERWEIGHT given the confirmed death cross (10/50/200 SMA stack bearish at $103.29/$106.67/$103.91), widening negative MACD histogram at -0.60, and institutional distribution signature (27M-share event on 9/18), balanced against a real but two-tiered structural floor (Tier 1 at $99-101, Tier 2 at $94-97). The strategy calls for a 25-30% position trim via split-execution (50% at current $100-103 levels, 50% reserved for rallies into the $104-107 resistance cluster), with a hard closing stop at $99.95 on the residual core position and a $108.50 stop on tactical shorts.

Outcome

✓

Return

+0.22%

Status

scored

Maintain ABT as a Hold rating while executing an active 10-15% trim at current levels ($100-102) or on rallies to $104-106, capturing asymmetric upside if Q3 earnings delivers while reducing concentration risk if it disappoints; hard closing stop remains at $81.98 with a 1.5% portfolio risk cap, and zero net new exposure until a two-of-four catalyst-gated confirmation framework fires after Q3 2026 earnings (mid-October).

Outcome

✗

Return

-2.34%

Status

scored

Maintain Hold on ABT as the calibrated response to a conditional setup with conflicting signals. Trim 10-15% only on a confirmed rally into the $104-105 resistance cluster (200 SMA $104.05 / 50 SMA $106.41), with a hard closing stop at $99.95. Collect the 2.43% dividend yield while awaiting the Q3 2026 earnings binary catalyst (mid-October) that will resolve the debate between the structural floor ($7.4B FCF, 0.4x net debt/EBITDA, 54-year dividend streak) and the unresolved technical deterioration (price below all three MAs, MACD below zero at -0.62, RSI neutral at 41).

Outcome

✓

Return

-0.19%

Status

scored

Maintain ABT at the $103.69 entry zone with a hard stop at $97.74 (lower Bollinger band), avoiding new longs until technical confirmation arrives via sustained close above 200 SMA ($104.02) for 5+ sessions with RSI crossing 50. The 2.45% dividend yield provides carry while awaiting the Q3 2026 earnings binary catalyst to validate the $6.07 forward EPS and operating margin recovery to 16-18%.

Outcome

✓

Return

+0.69%

Status

scored

Maintain ABT at the trader's entry level of $103.50 with a hard closing stop at $97.50, executing a 10-15% trim into mid-October Q3 2026 earnings to reduce concentration risk while preserving upside optionality. The structural floor (Dividend King, $7.2B FCF, 0.4x net debt/EBITDA, 1.7x dividend coverage) limits downside while technical deterioration (all MAs above price, MACD -0.83, RSI 39) prevents conviction-sized longs; do not initiate new positions until either a confirmed close above 200 SMA ($104.11) on volume >25M shares or a capitulation flush to $93-95 with MACD/RSI confirmation occurs.

Outcome

–

Return

+0.36%

Status

scored

Underweight rating on ABT with a 30-40% position reduction via split execution (50% at market, 50% reserved for $104-106 rally), with hard closing stop at $98.50 on residual core position. The downgrade reflects unanimous bearish conviction across all analysts with price below all three moving averages (10 EMA, 50 SMA, 200 SMA), an imminent death cross, and deteriorating fundamentals including 65% sequential FCF collapse, ROE below WACC, and negative tangible book; risk/reward favors trim at $102.61 with ~7-8% downside to support versus ~5-7% upside to resistance. Re-engagement requires two-of-four confirmations (200 SMA reclaim with volume, MACD higher low, RSI bullish divergence, or forward EPS stabilization) while maintaining reduced exposure to collect the 2.47% dividend through the Q2/Q3 2026 earnings binary catalyst.

Outcome

✓

Return

+0.37%

Status

scored

Hold ABT with disciplined execution pending Q3 2026 catalyst resolution. The aggressive analyst's valuation case (16.85x forward P/E, $7.2B FCF, 2.46% yield) is compelling but unvalidated against integration results, while the conservative analyst's balance sheet concerns (gross debt up 145% to $34B, negative tangible book, ROE compressed to 10.6%) represent a structural risk change. Price below all three moving averages with expanding negative MACD (-1.21) and RSI at 36.40 prevents conviction-sized positioning in either direction.

Outcome

–

Return

-0.13%

Status

scored

Adopt an Overweight rating on ABT with a $115 price target over 6-12 months, building a 4% position in 2-3 tranches starting with 2.5% on tests of $99-100 with RSI divergence, adding 1.5% on reversal above $103 with MACD contraction. The recommendation honors the 9/11 lesson that ABT's structural floor (50-year Aristocrat streak, $7.2B FCF, 1.7x dividend coverage) has repeatedly absorbed distribution, making conviction-sized Underweight the chronically late trade. Use a $96.50 hard stop (1.5x ATR cushion), avoid chasing strength above $104, and let forward EPS normalization toward $5.50-6.00 work over the holding period.

Outcome

✓

Return

+0.32%

Status

scored

Maintain current ABT position at current weight with Hold rating; trim 25-33% of position on any rally into $104-105 resistance zone, do not add below $102, and maintain hard closing stop at $99.96 (lower Bollinger band) with re-engagement only upon two of four confirmations including close above 200 SMA with volume, MACD higher low, RSI divergence, or EPS stabilization post-Q3 2026 earnings.

Outcome

✓

Return

-1.03%

Status

scored

Reduce ABT exposure by 20-25% to approximately 2-2.5% of healthcare allocation, initiating the trim at $104-105 within 1-3 sessions while reserving capacity to re-engage on any bounce to $107-108; hard stop set at $100.53 closing print (March swing low). The asymmetric risk profile favors this moderate trim: approximately 13% downside to $90 versus only 7% upside to $110, but the defensive floor (ABT's $7.2B FCF covering dividend at 1.7x, 54-year dividend Aristocrat streak, and 0.586 beta) prevents a full Sell rating. Re-engagement criteria include basing below $90, trend repair above $108, or Q3 margin recovery to 15%+.

Outcome

✗

Return

+1.12%

Status

scored

Maintain Underweight on ABT with immediate trim execution at $101-103, targeting 2-2.5% of healthcare allocation (~50% reduction). Use a $100.53 closing stop (rejecting the rejected $99.50 stop as fatally tight against $2.73 ATR), while preserving residual exposure due to the defensive floor ($7.2B FCF, 1.7x dividend coverage, 0.586 beta) and slow-burn catalysts (TactiFlex Duo, BSX share migration).

Outcome

✓

Return

-1.36%

Status

scored

ABT maintains HOLD rating at $103.36 with a modified 40-30-30 tiered accumulation framework rather than aggressive or conservative approaches; Tier 1 (40%) triggers on defense of $103 with RSI holding above 32 within 3-5 sessions, Tier 2 (30%) on reclaim of $107-108, and Tier 3 (30%) reserved for $96-100 downside or Q3 earnings validation. Hard stop is weekly close below $100 with immediate trim to Underweight, protecting against goodwill-impairment tail risk given 143% debt surge and 48% goodwill-to-assets ratio.

Outcome

✓

Return

-1.78%

Status

scored

Trim Abbott Laboratories 30-40% into any rally at $107-$108 (10 EMA), or at $105.23 if no relief bounce materializes within 1-2 weeks, while retaining 60-70% core position given the 54-year dividend streak and defensive floor (0.58 beta, 1.6x dividend coverage). Hard stop on retained core at $102.00 (~1.5x ATR below 50/200 SMA confluence), with re-engagement requiring either a confirmed close above $109.00 with MACD histogram positive for 2 consecutive sessions, a pullback to $98-$100 with RSI oversold below 32, or Q2 2026 earnings showing operating margin recovery to 15%+.

Outcome

✓

Return

-0.27%

Status

scored

Maintain ABT at Hold with benchmark weight allocation; do not add at the current $105.52 price. Replace the $115 February covered call with a $112 December strike to monetize 50-60% of premium while preserving upside participation through the Q2 2026 earnings catalyst. Implement tight invalidation discipline: close below $104.46 on volume > 9M triggers immediate trim to Underweight.

Outcome

✗

Return

-2.59%

Status

scored

Maintain ABT at current position size with Hold rating; the 9/3 reflection directly applies to this configuration with ATR-implied range ~1%, untested confluence support at $105.22-$106.55, and Q3 earnings binary catalyst still 4-6 weeks out. Hard stop at $103.50; escalate to 50% trim only on daily close below $104.00 with volume confirmation per the realized-momentum trigger requirement.

Outcome

–

Return

-0.42%

Status

scored

Trim Abbott to 70% benchmark weight (30% reduction) with hard stop on close below $102.50; re-engagement requires two of three triggers: 10 EMA/Bollinger mid reclaim with RSI >55, Q3 operating margin recovery to 15%+, or positive CMS CGM decision. The 30% trim captures asymmetric downside while preserving optionality in a quality defensive name ahead of the Q3 2026 earnings binary and year-end CMS CGM coverage catalyst.

Outcome

✓

Return

-1.52%

Status

scored

Trim ABT to 70-80% of benchmark weight with hard stop at $107.73, preserving defensive dividend aristocrat exposure while reducing concentration risk through the integration window. Re-entry at $103-105 requires EITHER operating margin recovery above 15% in Q3 2026 earnings OR technical reclaim of 10 EMA + 20 VWMA on rising volume. Re-evaluate at Q3 earnings (late October) and CMS Medicare CGM decision (year-end 2026); full exit warranted on daily close below $102.50 combined with continued margin compression.

Outcome

✗

Return

+1.41%

Status

scored

Trim Abbott Laboratories to 50-70% of target weight over 1-2 weeks using rallies into $110-112 as the execution window. Active stop at $109.50 close with hard stop at $102.50; re-engage only on 10 EMA reclaim with positive MACD histogram AND Q2/Q3 operating margin recovery above 16%. The thesis prioritizes the neutral analyst's operational refinement over more aggressive or conservative approaches, preserving upside participation while reducing exposure to front-loaded balance sheet deterioration.

Outcome

✓

Return

-1.30%

Status

scored

ABT maintains HOLD rating at $110-112, with a $122 price target over a 3-6 month horizon through Q3'26 earnings. The recommendation employs a three-tiered entry framework: 25-30% allocation on stabilization near $109.50 with RSI holding >50 and contracting MACD histogram, 30-40% at $105-107 on 200 SMA test, and 40% on confirmed breakout above $116 with volume >7M, while trimming 15% on close above $118 with volume >10M shares and maintaining a $103 hard stop.

Outcome

✗

Return

-1.88%

Status

scored

Maintain ABT at existing 1.5-2.5% portfolio weight without adding at $112.47, as technical deterioration (MACD bearish cross, below 10 EMA) and a transformed balance sheet (Net Debt +518% QoQ to $27.2B, D/E 63.2%) outweigh intact structural thesis ($7.4B FCF, Dividend King status, rich catalyst calendar). Require 2 of 4 confirmations before considering scaled adds: 10 EMA reclaim, Q2 earnings recovery, Medicare CGM surprise, or acquisition disclosure with credible integration timeline. Hard stop at $105; trim 15% on confirmed close above $118 with volume >10M shares.

Outcome

✓

Return

+0.79%

Status

scored

Maintain ABT at HOLD with a 1.5-2.5% portfolio weight ceiling and $103 hard stop; do not add at current $111.59 price. Trim 15% only on confirmed close above $118 with volume exceeding 10M shares, while the add trigger is set at $105-108 on reversal confirmation. Q3'26 earnings in late October represents a binary catalyst where margin recovery to 16-18% validates the structural thesis and supports an upgrade, while any continued margin compression warrants a downgrade to Underweight.

Outcome

✗

Return

-2.20%

Status

scored

Maintain ABT at modest defensive sizing (1.5-2.5% portfolio weight ceiling) and do not add at the current price of $114.10. The structural thesis remains intact (Dividend Aristocrat, $7.2B FCF, 0.58 beta, golden cross forming), and the current setup is less stretched than prior Underweight calls (RSI 66 vs 75+, MACD just rolling vs deeply compressed), making Hold the coherent rating with a price target of $122.

Outcome

✓

Return

-1.75%

Status

scored

Trim 40-45% of ABT at ~$116 via 2-3 tranches over 1-2 weeks to lock in gains from positions accumulated below $100, maintaining 55-60% core exposure. Reload capacity reserved at $102-105 (~55% of trim capital) and $95-98 (~45%), with tiered stops at $95 (hard) and ~$109 (trailing). Upgrade to Hold if price pulls back to $105 with RSI normalizing below 60 and MACD stabilization, or if price breaks above $117.88 on volume >7M with RSI re-accelerating.

Outcome

✓

Return

-0.46%

Status

scored

Maintain ABT at Hold as the structural thesis (CGM expansion, 200 SMA support flip, golden cross forming) remains intact while the tactical setup is overbought—RSI 77.97, MACD bearish divergence, price at upper Bollinger band $117.03 with zero margin of safety at 19x Forward P/E. Do not add at current levels; wait for pullback to $110-113 with confirmed higher-low structure and RSI reset toward 50-55, or asymmetric add on confirmed breakout above $117.03 on volume >7M shares.

Outcome

✓

Return

+0.03%

Status

scored

Maintain Abbott Laboratories (ABT) at Hold rating with 1.5-2.5% portfolio weight ceiling; the structural thesis is intact (Q2 2026 delivered 13% revenue growth, raised guidance, Cologuard recurring-revenue franchise, Dividend Aristocrat status) but current technicals are overbought—RSI at 77.93, price at $116.64 near upper Bollinger Band at $116.05, and MACD histogram compressed to +0.25 against new price highs. Do not add at current levels; wait for pullback into the $109-112 zone where RSI resets below 60.

Outcome

✗

Return

+2.19%

Status

scored

Maintain ABT at Hold with 1.5-2.0% portfolio weight ceiling as the structural trend (50 SMA +12% in seven weeks, raised FY guidance, golden cross forming 2-6 weeks, Alphabet Lingo + Medtronic MiniMed catalysts, $7.21B FCF) is constructive but immediate-term setup is overbought (RSI 74.49 with confirmed Aug 19 bearish divergence, MACD histogram compressed 88% from 1.11 to 0.13, three-day failure at $114.96 Bollinger upper band). Trail stop to $110.24 with trim below $110 on rising volume and full exit below $108.

Outcome

✓

Return

-0.25%

Status

scored

ABT remains on Hold as the technical setup (RSI 75.76, MACD histogram collapsed 88% from 1.11 to 0.13, price pinned to upper Bollinger Band) signals overbought exhaustion at $114.43 despite a fundamentally constructive thesis. Three analysts converge on Hold with tiered entry zones recommended: $110 for a starter add (1.5% weight) with stabilizing MACD histogram, or $107-108 for a full position (2.5% weight) with full technical confirmation including 200 SMA holding and RSI reset to 50-55. Thesis-based stop is at close below 200 SMA (~$105.94) on rising volume, with a 3-6 month horizon through Q3 2026 earnings as the binary catalyst.

Outcome

✗

Return

+1.55%

Status

scored

Reduce Abbott Laboratories (ABT) from benchmark weight to 50-60% via tranche-based trims over 1-2 weeks given an asymmetric risk-reward of 1.3:1 at $112.68 with RSI at 73.20, MACD histogram at 0.04 signaling nascent bearish divergence, and price 14.8% above the 50 SMA. The 35% rally in 14 weeks has created sufficient technical extension to warrant trimming, while franchise quality (0.58 beta, 2.27% yield, intact Dividend Aristocrat status, $105.50 200 SMA support) supports maintaining partial exposure rather than a full exit.

Outcome

✗

Return

+2.09%

Status

scored

Maintain ABT at neutral weight with the trader's framework executed exactly as written — the structural thesis (200 SMA support at $106, beta 0.58, 2.27% yield, intact Dividend Aristocrat status) remains intact, but the tactical tape (MACD histogram collapsed from +1.10 to ~0, RSI 69.2, 4.1% cushion to support) makes $110 a coin-flip entry with Q3 2026 earnings as the binary catalyst that will either justify upgrade to Overweight or trigger tactical downgrade. Neither the aggressive analyst's "load the add-zone" pressure nor the conservative analyst's "wait for $100 gift entry" framework improves risk-adjusted returns over the existing playbook.

Outcome

✓

Return

-0.79%

Status

scored

Maintain full ABT core position at $111.27 with tactical refinements pending Q3 2026 earnings catalyst. The aggressive analyst's $133.79 anchor is rejected due to materially different balance sheet (debt expanded from $13.8B to $34B), while the neutral analyst's partial-profit trim is rejected as it would forfeit compounding in a rangebound defensive name paying 2.3% yield. New entrants stage half-size at $108.27 (10 EMA) with confirmation, second half on breakout above $112.70 above 12M shares. Stop unchanged at $98.50.

Outcome

–

Return

-0.02%

Status

scored

Reduce ABT exposure by 15-20% given RSI 73, upper Bollinger test at $112.70, multiple rejections at $114-115, and 86% sequential collapse in buyback run-rate as management pivots to deleveraging; re-enter at $102-105 (Tier 1) or $98-100 (Tier 2) with $96 hard stop, targeting $122 over 3-6 months through Q2 2026 EPS.

Outcome

✓

Return

+0.32%

Status

scored

ABT maintains Hold rating unanimous across all three analysts, balancing bullish fundamentals (Q2 beat-and-raise, 43% net debt reduction, Google Health Lingo partnership, dividend aristocrat profile) against bearish tactical signals (RSI 72.6, 87% to upper Bollinger Band at $112.16, PEG 2.19). Existing holders maintain and collect the 2.3% yield; new entrants cap at 2% portfolio weight and stage entries at $104–$106 and $100–$102 pullback levels, with a breakout trigger above $112.16 on volume >12M shares. $96.50 stop-loss and Q3 2026 earnings binary catalyst define the 3–6 month horizon with $122 price target.

Outcome

✓

Return

+1.08%

Status

scored

Maintain ABT at $109.72 with a Hold rating as the technical setup shows converging warnings (RSI 70.8 with bearish divergence, MACD collapsing 97%, 200 SMA declining) against a fundamentally sound franchise that beat on Q2 revenue and raised guidance. Deploy 40-45% now, reserve 55-60% for $103-106 weakness or $113.45 breakout, trim 25-40% into $110-113 resistance, and tighten stop to $106.30 (or $108 on hot CPI).

Outcome

✓

Return

+1.01%

Status

scored

ABT maintains a Hold rating unanimously across all analysts given intact franchise quality but conflicted technicals (RSI 69, stretched MACD) with no margin of safety at 17.9x forward P/E. A dual-pathway add framework is recommended: quarter-size increment on breakout above $114 with volume expansion, OR on pullback to $102-104 that holds 2-3 sessions with MACD confirmation. The $95 catastrophic stop and $102 secondary trim rule structure the position for the Q3 earnings catalyst that will validate or invalidate current pricing.

Outcome

✓

Return

+0.75%

Status

scored

Maintain ABT (Abbott Laboratories) as a Hold given the intact defensive compounder profile ($7.21B FCF, IG balance sheet, 1.6x dividend coverage) and reasonable 17.8x forward P/E, but avoid adding at current ~$107.81 into a descending 200 SMA with the August 12 CPI print approaching; re-engage with a conditional add of 25–33% of intended capital on two consecutive closes above $107.50 with RSI >65.